División de Medicina Interna, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, México; Departamento de Medicina Interna, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, México; Comité Estatal de Tuberculosis Farmacorresistente, San Luis Potosí, México.
División de Medicina Interna, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, México; Departamento de Medicina Interna, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, México; Comité Estatal de Tuberculosis Farmacorresistente, San Luis Potosí, México.
Arch Med Res. 2015 Feb;46(2):142-8. doi: 10.1016/j.arcmed.2015.01.006. Epub 2015 Feb 19.
Multidrug resistant tuberculosis (MDR-TB) poses problems in treatment, costs and treatment outcomes. It is not known if classically described risk factors for MDR-TB in other countries are the same in Mexico and the frequency of the association between diabetes mellitus (DM) and MDR-TB in our country is not clear. We undertook this study to analyze risk factors associated with the development of MDR-TB, with emphasis on DM.
A case-control study in the state of San Luis Potosi (SLP), Mexico was carried out. All pulmonary MDR-TB patients diagnosed in the state of SLP between 1998 and 2013 (36 cases) evaluated at a state pharmacoresistant tuberculosis (TB) clinic and committee; 139 controls were randomly selected from all pulmonary non-multidrug-resistant tuberculosis (non-MDR-TB) cases identified between 2003 and 2008. Cases and controls were diagnosed and treated under programmatic conditions.
Age, gender, malnutrition, being a health-care worker, HIV/AIDS status, and drug abuse were not significantly different between MDR-TB and non-MDR-TB patients. Significant differences between MDR-TB and non-MDR-TB patients were DM (47.2 vs. 28.1%; p = 0.028); previous anti-TB treatments (3 vs. 0, respectively; p <0.001), and duration of first anti-TB treatment (8 vs. 6 months, respectively; p <0.001).
MDR-TB and DM are associated in 47.2% of MDR TB cases (17/36) in this study. Other recognized factors were not found to be significantly different in MDR-TB compared to non-MDR-TB in this study. Cost-feasible strategies must be implemented in the treatment of DM-TB in order to prevent the selection of MDR-TB.
耐多药结核病(MDR-TB)在治疗、费用和治疗结果方面存在问题。目前尚不清楚在其他国家经典描述的 MDR-TB 危险因素是否与墨西哥相同,也不清楚我国糖尿病(DM)与 MDR-TB 之间的关联频率。我们进行了这项研究,以分析与 MDR-TB 发展相关的危险因素,重点是 DM。
在墨西哥圣路易斯波托西州(SLP)进行了一项病例对照研究。在州抗药性肺结核(TB)诊所和委员会评估的 1998 年至 2013 年间在该州诊断的所有肺 MDR-TB 患者(36 例);从 2003 年至 2008 年期间确定的所有肺非耐多药结核病(非-MDR-TB)病例中随机选择了 139 名对照。病例和对照在规划条件下进行诊断和治疗。
MDR-TB 和非 MDR-TB 患者之间在年龄、性别、营养不良、医疗保健工作者、艾滋病毒/艾滋病状态和药物滥用方面没有显著差异。MDR-TB 和非 MDR-TB 患者之间的显著差异为糖尿病(47.2%与 28.1%;p = 0.028);先前的抗结核治疗(分别为 3 例与 0 例;p<0.001),以及首次抗结核治疗的持续时间(分别为 8 个月与 6 个月;p<0.001)。
在这项研究中,36 例 MDR-TB 患者中有 47.2%(17/36)与 DM 相关。在这项研究中,与非 MDR-TB 相比,其他公认的因素在 MDR-TB 中没有发现明显差异。必须实施具有成本效益的策略来治疗 DM-TB,以防止 MDR-TB 的选择。